Barclays initiated coverage of Cencora (COR) with an Overweight rating and $400 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora, Inc. Faces Business Risks from Unpredictable Global Events
- Cencora price target raised to $417 from $344 at JPMorgan
- Cencora price target raised to $405 from $354 at Wells Fargo
- Cencora price target raised to $400 from $350 at TD Cowen
- Cencora price target raised to $371 from $322 at Deutsche Bank